Results 101 to 110 of about 12,212 (162)

Telmisartan-induced lichenoid drug eruption: a case report [PDF]

Lichenoid drug eruption (LDE) is a rare adverse reaction to various medications, including antihypertensives like telmisartan. Early identification and withdrawal of the offending agent are key to management.
Vadgama, Vishalkumar K., Sanghani, Palak C., Navadiya, Trunali C., Patel, Jaimish S.   +3 more
core   +1 more source

14.EVALUATION OF THE ANTI-INFLAMMATORY EFFECT OF TELMISARTAN AS AN ADJUVANT THERAPY TO NSAID IN THE MANAGEMENT OF KNEE OSTEOARTHRITIS; A CLINICAL PROSPECTIVE STUDY

The Iraqi Journal of Medical Sciences, 2018
Background: Osteoarthritis (OA) is a degenerative joint disease caused by gradual loss of cartilage. Telmisartan is an angiotensin II receptor antagonist, and act as a partial agonist on the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-?
Sarah A. Hmood, Mohammed M. Mohammed, Yassir M. Kamal, Nizar A. Jasim   +3 more
doaj   +2 more sources

Telmisartan-induced NO production is suppressed by p38 MAPK inhibition.

, 2014
Intracellular cGMP concentrations were measured to evaluate NO output from HUVECs treated with telmisartan after corrected for the protein concentration.
Daishi Fujita (564002), Hiroshi Satonaka (564004), Yasunobu Hirata (327829), Daisuke Nagata (564001), Masao Takahashi (360659), Ryozo Nagai (327830), Yoshiyuki Morishita (210781), Issei Komuro (48691), Arihiro Kiyosue (564003), Masahiro Myojo (564000), Tetsu Akimoto (564005)   +10 more
core   +1 more source

Telmisartan to prevent recurrent stroke - the PRoFESS study: was the baby thrown out with the bathwater? [PDF]

, 2008
McInnes, G.T., G. T. McInnes
core   +1 more source

New standards in hypertension and cardiovascular risk management: focus on telmisartan

Vascular Health and Risk Management, 2010
Domenico Galzerano1, Cristina Capogrosso4, Sara Di Michele2, Antonio Galzerano1, Paola Paparello1, Diana Lama3, Carlo Gaudio21Department of Cardiology, San Gennaro Hospital, Naples, Italy; 2Department of Heart and Great Vessels, A.
Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al   +3 more
doaj  

Cardioprotective Effects of Telmisartan against Heart Failure in Rats Induced By Experimental Autoimmune Myocarditis through the Modulation of Angiotensin-Converting Enzyme-2/Angiotensin 1-7/Mas Receptor Axis

International Journal of Biological Sciences, 2011
Angiotensin-converting enzyme-2 (ACE-2) is a homolog of ACE that preferentially forms angiotensin-(ANG)-1-7 from angiotensin II (ANG II). We investigated the cardioprotective effects of telmisartan, a well-known angiotensin receptor blockers (ARBs ...
Vijayakumar Sukumaran, Punniyakoti T. Veeraveedu, Narasimman Gurusamy, Ken'ichi Yamaguchi, Arun Prasath Lakshmanan, Meilei Ma, Kenji Suzuki, Makoto Kodama, Kenichi Watanabe
doaj  

Sustained antihypertensive activity of telmisartan vs valsartan [PDF]

, 2004
DBP reduction in the last 6 h of the once-daily dosing interval and 24-h mean DBP control when a dose is missed are significantly superior with telmisartan than with valsartan.
Lacourciere, Yves, Krzesinski, Jean-Marie, Oostvogel, L., Davidai, Giora, Schumacher, H., White, William   +5 more
core  

A process for the preparation of Telmisartan

, 2008
The present invention relates to a process for the preparation of Telmisartan by hydroxycarbonylation of compound of formula (V), wherein X is a substituent which can be transformed into a carboxy group by hydroxycarbonylation.
ROSSI, RENZO, CASTALDI GRAZIANO, Castaldi G., CAUTERUCCIO SILVIA, Rossi R, Cauteruccio S, BELLINA, FABIO   +6 more
core  

Use of cardiac magnetic resonance and echocardiography in population-based studies: why, where, and when? [PDF]

, 2013
Neubauer, S, Petersen, SE, Neubauer, Stefan, Marwick, TH   +3 more
core   +1 more source

Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats

Drug Design, Development and Therapy
Ying Li,1,2,* Wenyu Du,1– 3,* Chunhui Shan,4 Zefang Yu,1 Jing An,1,2 Zhanjun Dong1,2 1Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China; 2Hebei Key Laboratory of Clinical Pharmacy ...
Li Y, Du W, Shan C, Yu Z, An J, Dong Z
doaj